In addition, some scholars revealed that BRAF mutations were associated with markers of clinical aggressiveness such as larger tumors, lymph node metastases, and poor clinical outcomes (20). The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.